机构：招银国际 研究员：Jill WU/Andy WANG Differentiated ADC product pipeline. DualityBio has a robust pipeline of in-house discovered antibody-drug conjugate (ADC) candidates which is a testament to the Company's prowess in ADC innovation. DB- 1303/BNT323 (HER2 ADC)'s first indication (HER2-expressing EC) is projected to file FDA accelerated approval as early as 2025 as per the management. DB- 1311/BNT324 (B7-H3 ADC) is under development both as monotherapy and in combination with immunotherapy for SCLC, CRPC, among o ...